CorMedix Inc.

NasdaqGM:CRMD Rapporto sulle azioni

Cap. di mercato: US$688.7m

CorMedix Gestione

Gestione criteri di controllo 3/4

CorMedix Il CEO è Joe Todisco, nominato in May2022, e ha un mandato di 2.5 anni. la retribuzione annua totale è $ 2.46M, composta da 25.1% di stipendio e 74.9% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.3% delle azioni della società, per un valore di $ 2.09M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.5 anni e 2.7 anni.

Informazioni chiave

Joe Todisco

Amministratore delegato

US$2.5m

Compenso totale

Percentuale dello stipendio del CEO25.1%
Mandato del CEO2.5yrs
Proprietà del CEO0.3%
Durata media del management2.5yrs
Durata media del Consiglio di amministrazione2.7yrs

Aggiornamenti recenti sulla gestione

Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns

Nov 14
Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns

Recent updates

Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns

Nov 14
Here's Why CorMedix Inc.'s (NASDAQ:CRMD) CEO Compensation Is The Least Of Shareholders' Concerns

Analysts Just Made A Massive Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts

Nov 04
Analysts Just Made A Massive Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts

CorMedix 2.0: New Leadership, New Approval, New Focus

Oct 28

CorMedix: Delayed Approval, Low Cash, Good Prospects

Oct 19

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Sep 30
We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth

Apr 06
We Think CorMedix (NASDAQ:CRMD) Can Afford To Drive Business Growth

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Nov 02
We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Jul 31
Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

CorMedix (NASDAQ:CRMD) Is In A Good Position To Deliver On Growth Plans

Feb 25
CorMedix (NASDAQ:CRMD) Is In A Good Position To Deliver On Growth Plans

FDA again rejects CorMedix's application for lead candidate DefenCath, shares sink ~60%

Aug 08

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Jul 16
Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Mar 01
We're Hopeful That CorMedix (NASDAQ:CRMD) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

Sep 09
Here's Why We're Not Too Worried About CorMedix's (NASDAQ:CRMD) Cash Burn Situation

CorMedix Inc.'s (NASDAQ:CRMD) Intrinsic Value Is Potentially 58% Above Its Share Price

Feb 11
CorMedix Inc.'s (NASDAQ:CRMD) Intrinsic Value Is Potentially 58% Above Its Share Price

We're Hopeful That CorMedix (NYSEMKT:CRMD) Will Use Its Cash Wisely

Jan 04
We're Hopeful That CorMedix (NYSEMKT:CRMD) Will Use Its Cash Wisely

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Joe Todisco rispetto agli utili di CorMedix?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

-US$46m

Jun 30 2024n/an/a

-US$53m

Mar 31 2024n/an/a

-US$50m

Dec 31 2023US$2mUS$617k

-US$46m

Sep 30 2023n/an/a

-US$40m

Jun 30 2023n/an/a

-US$37m

Mar 31 2023n/an/a

-US$33m

Dec 31 2022US$3mUS$378k

-US$30m

Compensazione vs Mercato: La retribuzione totale di Joe ($USD 2.46M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 3.21M ).

Compensazione vs guadagni: La retribuzione di Joe è stata coerente con le performance aziendali dell'ultimo anno.


AMMINISTRATORE DELEGATO

Joe Todisco (48 yo)

2.5yrs

Mandato

US$2,459,432

Compensazione

Mr. Joseph Todisco, also known as Joe, MBA, serves as Chief Executive Officer of CorMedix Inc. since May 10, 2022. He has served as Director of CorMedix Inc. since March 18, 2022 and served as its Independ...


Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Joseph Todisco
CEO & Director2.5yrsUS$2.46m0.30%
$ 2.1m
Matthew David
Executive VP & CFO4.5yrsUS$1.03m0.017%
$ 118.5k
Erin Mistry
Executive VP & Chief Commercial Officer4.7yrsUS$1.26m0.021%
$ 147.7k
Elizabeth Masson-Hurlburt
Executive VP and Chief Clinical Strategy & Operations Officerless than a yearUS$844.81k0.013%
$ 89.6k
Kaufman Zelnick
Executive VPless than a yearNessun datoNessun dato
Donna Ucci
Senior VP & Head of Global Quality2.5yrsNessun datoNessun dato
Tushar Mukherjee
Senior VP & Head of Technical Operations1.8yrsNessun datoNessun dato

2.5yrs

Durata media

47yo

Età media

Gestione esperta: Il team dirigenziale di CRMD è considerato esperto (durata media dell'incarico 2.5 anni).


Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Joseph Todisco
CEO & Director2.7yrsUS$2.46m0.30%
$ 2.1m
Myron Kaplan
Independent Chairman of the Board8.6yrsUS$191.96k0.30%
$ 2.1m
Alan Dunton
Independent Director5.7yrsUS$141.42k0.025%
$ 173.1k
Janet Dillione
Independent Director9.3yrsUS$147.42k0.088%
$ 606.9k
Steven Lefkowitz
Independent Director7.4yrsUS$162.42k0.13%
$ 879.6k
Gregory Duncan
Independent Director4yrsUS$141.42k0%
$ 0
Bruce Polsky
Member of Scientific Advisor Boardno dataNessun datoNessun dato
Saravanan Balamuthusamy
Member of Scientific Advisory Board2.6yrsNessun datoNessun dato
Sara Bonnes
Member of Scientific Advisory Board2.6yrsNessun datoNessun dato
Aru Narendran
Member of Scientific Advisory Board2.6yrsNessun datoNessun dato
Hannah Newman
Member of Scientific Advisory Board2.6yrsNessun datoNessun dato
Jonathan Waitman
Member of Scientific Advisory Board2.6yrsNessun datoNessun dato

2.7yrs

Durata media

68yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di CRMD non è considerato esperto (durata media del mandato 2.7 anni), il che suggerisce un nuovo consiglio.